MUSCULAR DYSTROPHY, MUSCULAR ATROPHY, MYASTHENIA GRAVIS AND STRABISMUS

Publisher Website
Google Scholar
Abstract
Following the contributions of Aran,1Charcot,2Marie and others the essential pathologic lesions responsible for the various myopathies have been diligently studied. Still these attempts have resulted in few fruitful rewards. At present, with the usual standards of diagnosis, accurate determination of the etiologic factors in most of these cases taxes the diagnostic acumen of the best trained clinicians. It seems desirable, therefore, to study the various myopathies, from a metabolic as well as from a clinical point of view, with the aim of evolving observations that may have diagnostic and prognostic applications as well as distinct therapeutic value. The advent of amino acid therapy in the treatment of myasthenia gravis, primary muscular dystrophy and secondary muscular atrophy has opened such vast and comparatively fertile fields of scientific endeavor that it appears that the biochemical investigation of these cases should result in many interesting and important contributions, particularly

This publication has 0 references indexed in Scilit: